🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Denmark / NCT06628323
Active, not recruiting Not applicable

Neuro-VR: Augmenting a Virtual Reality-based Therapy With Biofeedback for Auditory Hallucinations

NCT06628323 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2024-11-12
Last updated
2026-05-06

Condition(s) studied

Auditory HallucinationsSchizophrenia

Investigational drug(s) / intervention(s)

Virtual Reality-based Intervention employing NeurofeedbackVirtual Reality-based Intervention

Virtual Reality-based Intervention employing Neurofeedback: Virtual Reality-based intervention augmented with real-time EEG-based neurofeedback targeting auditory hallucinations in schizophrenia

Virtual Reality-based Intervention: Virtual Reality-based intervention targeting auditory hallucinations in schizophrenia

Study summary

The primary goal of this pilot study is to examine the feasibility and acceptability of augmenting a Virtual Reality-based intervention for treating auditory hallucinations in schizophrenia with electroencephalogram (EEG)-based neurofeedback.

The main questions it aims to answer are:

1. Is Virtual Reality -based therapy supplemented with EEG-based neurofeedback (VR-NF) a feasible and acceptable treatment for auditory hallucinations?
2. Will VR-NF show indications of being more effective than Virtual Reality-based therapy alone in reducing the severity of auditory hallucinations, improving daily functioning, and enhancing quality of life?

Researchers will compare VR-NF to Virtual Reality-based therapy alone to evaluate therapy effectiveness.

Participants will be allocated to receive 8 sessions of either VR-NF or Virtual Reality-based therapy alone. All participants will undergo a thorough assessment at baseline, and at 12 weeks post-baseline.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: 1. Ability to give informed consent 2. Age of 18-65 years 3. Diagnosis of schizophrenia spectrum disorder (ICD-10 codes: F20, F22-23; F25-29) 4. Symtoms of Auditory Verbal Hallucinations within at least the past 3 months (corresponding to SAPS score of 3 or more) 5. Identification of at least one dominant voice 6. No changes in antipsychotic medications four weeks prior to inclusion in the project 7. No planned changes in antipsychotic medication in the 12 weeks following inclusion in the project 8. A command of Danish or English sufficient to engage in therapy Exclusion Criteria: 1. Rejecting informed consent 2. A diagnosis of organic brain disease 3. Intellectual disability (IQ ˂ 70) 4. A primary diagnosis of substance dependence hindering engaging in therapy 5. Hear voices in a language the therapist does not speak 6. Inability to tolerate the therapy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Copenhagen Research Center for Mental Health - CORE Copenhagen Hellerup

More University Hospital Bispebjerg and Frederiksberg trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06628323 on ClinicalTrials.gov ↗ ← All trials in Denmark